Azacitidine Injection, Powder, Lyophilized, For Solution
Product Images NDC 43598-305

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Azacitidine (NDC 43598-305). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton Cipla

This is a pharmaceutical product. It is a lyophilized toxic substance, available in a single vial of 100 mg/vial, to be diluted for subcutaneous and intravenous use only. The manufacturer is Dr. Reddy's. The text also includes some dosage instructions and disposal guidelines. However, the text seems to be incomplete and contains errors.*

FDA Label Image

Carton (Carton)

This is a description of Azacitidine injections used for subcutaneous and intravenous use. The injections come in a lyophilized form and must be diluted before use. Each vial contains 100mg of Azacitidine. The text also provides instructions for the storage of the injections.*

FDA Label Image

Vial Cipla

Description: This is a medication that comes in a single-dose vial with 100 mg powder for subcutaneous and intravenous use. The medication is a cytotoxic agent that needs to be diluted before use. The text also includes some brand or manufacturer's name and some unreadable characters, which are not relevant to describe the medication.*

FDA Label Image

Vial (Vial)

FDA Label Image

Graph (Graph)

This is a survival analysis between two groups (AZA and CCR) and the log-rank test shows a statistically significant difference (p=0.0001) in their survival rates over time. The hazard ratio for AZA compared to CCR is 0.58 (95% CI: 0.43-0.77) meaning AZA has lower risk of death. The number of deaths for AZA and CCR are 82 and 113 respectively. The graph shows the proportion of patients surviving over time (in months) for both groups.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.